Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer
Na Zhao(Baylor College of Medicine), Jeffrey M. Rosen(Baylor College of Medicine), Clark Hamor(Baylor College of Medicine), Sara R. Savage(Baylor College of Medicine), Yang Gao(Baylor College of Medicine), Diego A. Pedroza(Texas Tech University), Kazem Safari(Texas A&M Health Science Center), Alexander B. Saltzman, Elena B. Kabotyanski(Baylor College of Medicine), Charles M. Perou(University of North Carolina at Chapel Hill), Xueying Yuan(Baylor College of Medicine), Lucas C. Reineke(Baylor College of Medicine), Susan G. Hilsenbeck(Baylor College of Medicine), Nadia Lieu(Baylor College of Medicine), Bing Zhang(Baylor Genetics), Jianling Zhou(The University of Texas MD Anderson Cancer Center), Cheng Fan(University of North Carolina at Chapel Hill), Luisa M. Solis(The University of Texas MD Anderson Cancer Center), Anna Malovannaya(Baylor College of Medicine), Sebastian J. Calderon(Baylor College of Medicine), Alex J. Smith(Baylor College of Medicine)
Cited by 3
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
The molecular portraits of breast tumors are conserved across microarray platforms
|BMC Genomics|2006|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k